DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties

References

• Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340:1330-40; PMID:10219069; http://dx.doi.org/10.1056/NEJM199904293401706
   PubMed Web of Science ®Google Scholar
• Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247:1079-82; PMID:2408149; http://dx.doi.org/10.1126/science.2408149
   PubMed Web of Science ®Google Scholar
• Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824-30; PMID:2406902; http://dx.doi.org/10.1126/science.2406902
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408-17; PMID:17151364; http://dx.doi.org/10.1056/NEJMoa062867
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Gugliotta G, Palandri F, Baccarani M. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Crit Rev Oncol Hematol 2012; 82:159-70; PMID:21565522; http://dx.doi.org/10.1016/j.critrevonc.2011.04.002
   PubMed Web of Science ®Google Scholar
• Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia. Leukemia 2013; 27:803-12; PMID:23238589; http://dx.doi.org/10.1038/leu.2012.313
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6:1018-23; PMID:10973322; http://dx.doi.org/10.1038/79526
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041-50; PMID:7655033
   PubMed Web of Science ®Google Scholar
• Oji Y, Oka Y, Nishida S, Tsuboi A, Kawakami M, Shirakata T, Takahashi K, Murao A, Nakajima H, Narita M, et al. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. Eur J Haematol 2010; 85:358-60; PMID:20633041; http://dx.doi.org/10.1111/j.1600-0609.2010.01497.x
   PubMed Web of Science ®Google Scholar
• Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87:3587-92; PMID:8611681
   PubMed Web of Science ®Google Scholar
• Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000; 95:1781-7; PMID:10688838
   PubMed Web of Science ®Google Scholar
• Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103:1037-42; PMID:14504104; http://dx.doi.org/10.1182/blood-2003-03-0954
   PubMed Web of Science ®Google Scholar
• Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007; 21:2287-95; PMID:17637811; http://dx.doi.org/10.1038/sj.leu.2404858
   PubMed Web of Science ®Google Scholar
• Rezvani K. PR1 vaccination in myeloid malignancies. Expert Rev Vaccines 2008; 7:867-75; PMID:18767937; http://dx.doi.org/10.1586/14760584.7.7.867
   PubMed Web of Science ®Google Scholar
• Westermann J, Kopp J, van Lessen A, Hecker AC, Baskaynak G, le Coutre P, Dohner K, Dohner H, Dorken B, Pezzutto A. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol 2007; 137:297-306; PMID:17408402; http://dx.doi.org/10.1111/j.1365-2141.2007.06547.x
   PubMed Web of Science ®Google Scholar
• Westermann J, Korner IJ, Kopp J, Kurz S, Zenke M, Dorken B, Pezzutto A. Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties. Cancer Immunol Immunother 2003; 52:194-8; PMID:12649749
   PubMed Web of Science ®Google Scholar
• Westermann J, Lessen A, Schlimper C, Baskaynak G, le Coutre P, Dorken B, Pezzutto A. Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia. Br J Haematol 2006; 132:32-5; PMID:16371017; http://dx.doi.org/10.1111/j.1365-2141.2005.05844.x
   PubMed Web of Science ®Google Scholar
• Westermann J, Schlimper C, Richter G, Mohm J, Dorken B, Pezzutto A. T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia. Br J Haematol 2004; 125:213-6; PMID:15059144; http://dx.doi.org/10.1111/j.1365-2141.2004.04873.x
   PubMed Web of Science ®Google Scholar
• Bocchia M, Defina M, Aprile L, Ippoliti M, Crupi R, Rondoni M, Gozzetti A, Lauria F. Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination. Nat Rev Clin Oncol 2010; 7:600-3; PMID:20808301; http://dx.doi.org/10.1038/nrclinonc.2010.141
   PubMed Web of Science ®Google Scholar
• Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009; 114:1528-36; PMID:19420358; http://dx.doi.org/10.1182/blood-2008-09-179697
   PubMed Web of Science ®Google Scholar
• Aurelius J, Martner A, Riise RE, Romero AI, Palmqvist L, Brune M, Hellstrand K, Thoren FB. Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes. J Leukoc Biol 2013; 93:155-60; PMID:23072905; http://dx.doi.org/10.1189/jlb.0512257
   PubMed Web of Science ®Google Scholar
• Miyazono K. Tumour promoting functions of TGF-β in CML-initiating cells. J Biochem 2012; 152:383-5; PMID:22989931; http://dx.doi.org/10.1093/jb/mvs106
   PubMed Web of Science ®Google Scholar
• Christiansson L, Soderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, Olsson-Stromberg U, Loskog AS. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One 2013; 8:e55818; PMID:23383287; http://dx.doi.org/10.1371/journal.pone.0055818
   PubMed Web of Science ®Google Scholar
• Mumprecht S, Claus C, Schurch C, Pavelic V, Matter MS, Ochsenbein AF. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. Blood 2009; 113:4681-9; PMID:19252140; http://dx.doi.org/10.1182/blood-2008-05-156471
   PubMed Web of Science ®Google Scholar
• Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990; 172:631-40; PMID:2373994; http://dx.doi.org/10.1084/jem.172.2.631
   PubMed Web of Science ®Google Scholar
• Westermann J, Kopp J, Korner I, Richter G, Qin Z, Blankenstein T, Dorken B, Pezzutto A. Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia. Bone Marrow Transplant 2000; 25 Suppl 2:S46-9; PMID:10933188; http://dx.doi.org/10.1038/sj.bmt.1702354
   PubMedGoogle Scholar
• Ossenkoppele GJ, Stam AG, Westers TM, de Gruijl TD, Janssen JJ, van de Loosdrecht AA, Scheper RJ. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 2003; 17:1424-6; PMID:12835739; http://dx.doi.org/10.1038/sj.leu.2402979
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tanaka Y, Nieda M, Azuma T, Chiba S, Juji T, Shibata Y, Hirai H. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res 2003; 27:795-802; PMID:12804637; http://dx.doi.org/10.1016/S0145-2126(03)00011-0
   PubMed Web of Science ®Google Scholar
• Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, et al. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy 2006; 8:290-8; PMID:16793737; http://dx.doi.org/10.1080/14653240600735743
   PubMed Web of Science ®Google Scholar
• Li Y, Lin C, Schmidt CA. New insights into antigen specific immunotherapy for chronic myeloid leukemia. Cancer Cell Int 2012; 12:52; PMID:23241263; http://dx.doi.org/10.1186/1475-2867-12-52
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I, Schendel DJ. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med 2007; 5:18; PMID:17430585; http://dx.doi.org/10.1186/1479-5876-5-18
   PubMed Web of Science ®Google Scholar
• Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000; 164:4507-12; PMID:10779751; http://dx.doi.org/10.4049/jimmunol.164.9.4507
   PubMed Web of Science ®Google Scholar
• Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. α-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64:5934-7; PMID:15342370; http://dx.doi.org/10.1158/0008-5472.CAN-04-1261
   PubMed Web of Science ®Google Scholar
• Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997; 90:1920-6; PMID:9292525
   PubMed Web of Science ®Google Scholar
• Kalinski P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapsenberg ML. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 1999; 162:3231-6; PMID:10092774
   PubMed Web of Science ®Google Scholar
• Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res 2011; 50:235-47; PMID:21717071; http://dx.doi.org/10.1007/s12026-011-8224-z
   PubMed Web of Science ®Google Scholar
• Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184:747-52; PMID:8760829; http://dx.doi.org/10.1084/jem.184.2.747
   PubMed Web of Science ®Google Scholar
• Zaccard CR, Watkins SC, Kalinski P, Fecek RJ, Yates AL, Salter RD, Ayyavoo V, Rinaldo CR, Mailliard RB. CD40L induces functional tunneling nanotube networks exclusively in dendritic cells programmed by mediators of type 1 immunity. J Immunol 2015; 194:1047-56; PMID:25548234; http://dx.doi.org/10.4049/jimmunol.1401832
   PubMed Web of Science ®Google Scholar
• Kalinski P. Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs 2009; 10:526-35; PMID:19513941
   PubMed Web of Science ®Google Scholar
• Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8:237-49; PMID:12766484; http://dx.doi.org/10.1023/A:1023668705040
   PubMed Web of Science ®Google Scholar
• Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, Young NS, Maciejewski JP. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood 1997; 89:957-64; PMID:9028327
   PubMed Web of Science ®Google Scholar
• Bhatia R, Verfaillie CM. The effect of interferon-α on β-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia. Leuk Lymphoma 1998; 28:241-54; PMID:9517496
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, et al. Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97:1033-41; PMID:12569603; http://dx.doi.org/10.1002/cncr.11223
   PubMed Web of Science ®Google Scholar
• Krusch M, Salih HR. Effects of BCR-ABL inhibitors on anti-tumor immunity. Curr Med Chem 2011; 18:5174-84; PMID:22087818; http://dx.doi.org/10.2174/092986711798184271
   PubMed Web of Science ®Google Scholar
• Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, Amabile M, Forconi F, Gozzetti A, Raspadori D, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365:657-62; PMID:15721470; http://dx.doi.org/10.1016/S0140-6736(05)70931-4
   PubMed Web of Science ®Google Scholar
• Eibl B, Ebner S, Duba C, Bock G, Romani N, Erdel M, Gachter A, Niederwieser D, Schuler G. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 1997; 20:215-23; PMID:9365828; http://dx.doi.org/10.1002/(SICI)1098-2264(199711)20:3%3c215::AID-GCC1%3e3.0.CO;2-5
   PubMed Web of Science ®Google Scholar
• Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89:1133-42; PMID:9028934
   PubMed Web of Science ®Google Scholar
• Tong XM, Yao HP, Qian WB, Zhu LF, Fu ZH, Huang ZL, Jin J. The biological characteristics of dendritic cells derived in vitro from myelogeneous leukemia cells and healthy donor cells. Int J Lab Hematol 2008; 30:372-81; PMID:18205840; http://dx.doi.org/10.1111/j.1751-553X.2007.00986.x
   PubMed Web of Science ®Google Scholar
• Westermann J, Florcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A, Johrens K, Lukowsky A, Schonemann C, Sawitzki B, et al. Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Ther 2011; 18:354-63; PMID:21068778; http://dx.doi.org/10.1038/gt.2010.143
   PubMed Web of Science ®Google Scholar